• LAST PRICE
    0.3666
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.3501/ 11
  • Ask / Lots
    0.3666/ 1
  • Open / Previous Close
    0.0000 / 0.3666
  • Day Range
    ---
  • 52 Week Range
    Low 0.3411
    High 1.7500
  • Volume
    111
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.37
TimeVolumeHOTH
09:34 ET36050.365
09:38 ET48700.361
09:39 ET67000.3612
09:50 ET6000.3692
10:06 ET3000.3612
10:12 ET4000.3651
10:19 ET28000.3694
10:26 ET4400.36515
10:46 ET1000.3652
11:06 ET6000.3694
11:58 ET1000.363681
12:02 ET5100.3625
12:03 ET44000.3631
12:14 ET18000.3601
12:45 ET12890.3631
01:51 ET1000.365
02:42 ET1000.3679
03:00 ET3000.365
03:41 ET28000.367
03:50 ET4000.367
03:54 ET6000.369
03:57 ET28030.3666
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesHOTH
Hoth Therapeutics Inc
11.9M
-0.8x
---
United StatesNLBS
Nutralife Biosciences Inc
12.4M
-2.3x
---
United StatesTRCNF
Transnational Cannabis Ltd
10.7M
0.0x
---
United StatesCLTS
Earth Life Sciences Inc
7.2M
-16.0x
---
United StatesSBFM
Sunshine Biopharma Inc
15.6M
-0.5x
---
United StatesAKAN
Akanda Corp
15.7M
-1.4x
---
As of 2022-09-28

Company Information

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for unmet medical needs. The Company is also focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer; a treatment for mast-cell derived cancers and anaphylaxis, and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases. The Company’s preclinical assets for atopic dermatitis; treatment for asthma and allergies using inhalational administration; a treatment for lung diseases resulting from bacterial infections, and treatment for inflammatory bowel diseases. The Company is also developing a diagnostic device via a mobile device. Its primary development products include HT-001, HT-KIT and HT-ALZ. Its preclinical development products include HT-003, HT-004, HT-006 and HT-002. It is also developing a COVID-19 treatment as well as a diagnostic device for the detection of viruses via a mobile device.

Contact Information

Headquarters
701 S Carson St Ste 200NEW YORK, NY, United States 10020-2003
Phone
551-578-2261
Fax
---

Executives

President, Chief Executive Officer, Director
Robb Knie
Chief Financial Officer
David Briones
Chief Scientific Officer
Stefanie Johns
Vice President - Operations
Jane Springer
Independent Director
Wayne Linsley

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$11.9M
Revenue (TTM)
$0.00
Shares Outstanding
32.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.92
EPS
$-0.48
Book Value
$0.41
P/E Ratio
-0.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.